Comparison of the efficacy of chemotherapy and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first remission in adults

The aim of the study was to compare the efficacy of allogeneic hematopoietic stem cell transplantation (alloHSCT) and chemotherapy (CT) of acute myeloid leukemia (AML) in first remission (CR1), to identify factors influencing the results. We compare the efficacy alloHSCT in CR1 (n = 70) and CT (n = 52). Patients were stratified by age, the level of leucocytes, the origin of AML, cytogenetic risk group and response to induction CT. Five-years overall and disease-free survival (OS and DFS) were higher in the group alloHSCT (67 and 65 % vs 46 and 30 % (p = 0.02 and p = 0.001)). Benefits of DFS after alloHSCT was in standard and high-risk cytogenetic groups (78 % versus 29 % (p = 0.001), and 34 % vs 17 % (p = 0.007)). The risk of relapse (RR) was 24 % in patients after alloHSCT vs. 57 % for CT (p = 0.003). Comparing the RR after alloHSCT and CT depending on the cytogenetic risk groups: standard (HR0.2(CI95 %0.07 - 0.56) p = 0.002), and high (HR0.27(CI95 %0.08-0.86) p = 0.03). Additional factors affect the RR were the origin of AML (de novo) (HR0.47 (CI95 %0.3-0.74) p = 0.001), the hyperleukocytosis (HR1.91 (CI95 %1.09 - 3.32) p = 0.02), and no remission after the first course CT (HR3.32(CI95 %1.57-7.0) p = 0.002). The efficacy of alloHSCT compared with CT is higher both in standard and high-risk cytogenetic group.

острый миелоидный лейкоз, химиотерапия, трансплантация костного мозга, acute myeloid leukemia, chemotherapy, allogeneic hematopoietic stem cell transplantation

1. Dores G.M. et al. Acute leukemia incidence and patient survival among children and adults in the United States. 2001 - 2007 // Blood. - 2012. - № 119 (1). -Р. 34-43.

2. Swerdlow S.H. et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues: International Agency for Research on Cancer. - 4th ed. - Lyon: IARC Press, 2008.

3. Dohner H. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia // Net. Blood. - 2010. - № 115. -Р. 453-474.

4. Parovichnikova E.N. et al. Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results // Ter. Arkh. - 2014. - № 86 (7). - Р. 14-23.

5. Burnett A.K., Hills R.K., Milligan D.W. et al. Attempts to Optimize Induction and Consolidation Treatment in Acute Myeloid Leukemia: Results of the MRC AML12 Trial // J. Clin. Oncol. - 2010. - № 28. - Р. 586-595.

6. Schaich M., Rollig C., Soucek S. et al. Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia: results of patients enrolled onto the prospective randomized AML96 study // J. Clin. Oncol. - 2011. -№ 29. - Р. 2696-2702.

7. Parovichnikova E.N. et al. The results of a multicenter randomized trial on the treatment of acute myeloid leukemia of adults // Ter. Arkh. - 2010. - № 82 (7). - Р. 5-11.

8. Afanasyev B.V. et al. The experience in non-relative allogeneic transplantation of stem hemopoietic cells in the Clinic of Bone Marrow Transplantation at I. P. Pavlov St-Petersburg Medical Academy // Ter. Arkh. - 2007. - № 79 (7). - Р. 36-43.

9. Bondarenko S.N. et al. Allogeneic hematopoietic stem cell transplantation for acute myeloblastic leukemia in first remission // Ter. Arkh. - 2013. - № 85 (7). - Р. 18-25.

10. Suciu S. et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial // Blood. - 2003. - № 102 (4). - Р. 1232-1240.

11. Cornelissen J.J. et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? // Blood. - 2007. - № 109 (9). - Р. 3658-3666.

12. Cornelissen J.J. et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach // Nat. Rev. Clin. Oncol. - 2012. - № 150. - Р. 1-12.

13. de Lima M. et al. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelo-dysplastic syndrome: a dose and schedule finding study // Cancer. - 2010. - № 116 (23). - Р. 5420-5431.